Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
11.54
+0.05 (0.44%)
At close: Mar 6, 2026, 4:00 PM EST
11.42
-0.12 (-1.04%)
After-hours: Mar 6, 2026, 7:44 PM EST
Omeros Employees
Omeros had 202 employees as of December 31, 2024. The number of employees increased by 4 or 2.02% compared to the previous year.
Employees
202
Change (1Y)
4
Growth (1Y)
2.02%
Revenue / Employee
n/a
Profits / Employee
-$599,797
Market Cap
818.19M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Phathom Pharmaceuticals | 371 |
| KalVista Pharmaceuticals | 270 |
| Arvinas | 246 |
| CytomX Therapeutics | 121 |
| Janux Therapeutics | 109 |
| Annexon | 99 |
| Bright Minds Biosciences | 26 |
OMER News
- 18 days ago - Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program - Business Wire
- 5 weeks ago - Omeros Announces First Commercial Sales of YARTEMLEA® - Business Wire
- 2 months ago - Omeros Corporation (OMER) Discusses FDA Approval and Commercialization Plans for YARTEMLEA in TA-TMA Treatment Transcript - Seeking Alpha
- 2 months ago - Omeros prices transplant complication drug at $36,000 per dose - Reuters
- 2 months ago - Omeros Announces New Date for YARTEMLEA® Approval Conference Call - Business Wire
- 2 months ago - Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely - Seeking Alpha
- 2 months ago - Gold Edges Lower; Omeros Shares Jump - Benzinga
- 2 months ago - US FDA approves Omeros' drug to treat dangerous transplant complication - Reuters